Gastrointestinal Stromal Tumor: New Insights for a Multimodal Approach

Ashwyn K Sharma; Teresa S Kim; Sebastian Bauer; Jason K Sicklick

doi:10.1016/j.soc.2022.03.007

Gastrointestinal Stromal Tumor: New Insights for a Multimodal Approach

Surg Oncol Clin N Am. 2022 Jul;31(3):431-446. doi: 10.1016/j.soc.2022.03.007. Epub 2022 May 31.

Authors

Ashwyn K Sharma¹, Teresa S Kim², Sebastian Bauer³, Jason K Sicklick⁴

Affiliations

¹ Department of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, CA, USA; Moores Cancer Center, University of California San Diego School of Medicine, 3855 Health Sciences Drive, Box 0987, La Jolla, CA 92093, USA.
² Department of Surgery, University of Washington, 1959 NE Pacific Street, Box 356410, Seattle, WA 98195, USA.
³ Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Hospital Essen Hufelandstr. 55, Essen 45122, Germany; DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany.
⁴ Department of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, CA, USA; Moores Cancer Center, University of California San Diego School of Medicine, 3855 Health Sciences Drive, Box 0987, La Jolla, CA 92093, USA. Electronic address: [email protected].

Abstract

Over the past 20 years, gastrointestinal stromal tumor (GIST) has evolved into an increasingly complex clinical entity with ever more challenges. While surgical resection is the gold standard, advancements in genetic testing, therapeutic options, immunotherapy, and management of metastatic disease necessitate a comprehensive, multimodal approach for these tumors. This chapter highlights the importance of genomic testing of GIST, the use of neoadjuvant and adjuvant therapy for localized disease, surgical principles for GIST, as well as current and new approaches for addressing metastatic disease.

Keywords: Gastrointestinal Stromal Tumor; Immunotherapy; Next Generation Sequencing; Tyrosine Kinase Inhibitors.

Publication types

Review

MeSH terms

Antineoplastic Agents* / therapeutic use
Combined Modality Therapy
Gastrointestinal Stromal Tumors* / genetics
Gastrointestinal Stromal Tumors* / surgery
Humans
Neoadjuvant Therapy

Substances

Antineoplastic Agents

Abstract

Publication types

MeSH terms

Substances

Grants and funding